ALUR Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -367.88% compared to Allurion Technologies's net margin of -18.58%. Allurion Technologies's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 266.38%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Allurion Technologies has higher upside potential than Retractable Technologies, analysts believe Allurion Technologies is more attractive than Retractable Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Allurion Technologies's net income of -$20.6M is lower than Retractable Technologies's net income of -$1.9M. Notably, Allurion Technologies's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.20x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -367.88% compared to Allurion Technologies's net margin of -1226.82%. Allurion Technologies's return on equity of -- beat VolitionRX's return on equity of --.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 266.38%. On the other hand VolitionRX has an analysts' consensus of $3.03 which suggests that it could grow by 469.23%. Given that VolitionRX has higher upside potential than Allurion Technologies, analysts believe VolitionRX is more attractive than Allurion Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.155, suggesting its more volatile than the S&P 500 by 15.463%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are larger than VolitionRX quarterly revenues of $474.5K. Allurion Technologies's net income of -$20.6M is lower than VolitionRX's net income of -$5.8M. Notably, Allurion Technologies's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.20x versus 37.34x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -367.88% compared to Allurion Technologies's net margin of -4291.67%. Allurion Technologies's return on equity of -- beat Catheter Precision's return on equity of -65.84%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 266.38%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 521.89%. Given that Catheter Precision has higher upside potential than Allurion Technologies, analysts believe Catheter Precision is more attractive than Allurion Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.775, suggesting its less volatile than the S&P 500 by 177.508%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are larger than Catheter Precision quarterly revenues of $96K. Allurion Technologies's net income of -$20.6M is lower than Catheter Precision's net income of -$4.1M. Notably, Allurion Technologies's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.20x versus 2.21x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -367.88% compared to Allurion Technologies's net margin of -10.04%. Allurion Technologies's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.34%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 266.38%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 272.34%. Given that Xtant Medical Holdings has higher upside potential than Allurion Technologies, analysts believe Xtant Medical Holdings is more attractive than Allurion Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.033, suggesting its less volatile than the S&P 500 by 103.341%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are smaller than Xtant Medical Holdings quarterly revenues of $31.5M. Allurion Technologies's net income of -$20.6M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Allurion Technologies's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.20x versus 0.54x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.